Friedreich Ataxia - Pipeline Review, H2 2018

Publisher Name :
Date: 11-Sep-2018
No. of pages: 91
Inquire Before Buying

Friedreich Ataxia - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Friedreich Ataxia - Pipeline Review, H2 2018, provides an overview of the Friedreich Ataxia (Central Nervous System) pipeline landscape.

Friedreich's ataxia (FA) is a neuromuscular disease that mainly affects the nervous system and the heart. FA is a hereditary disease, caused by a defective gene that can be passed down through a family. Signs and symptoms include ataxia, weakness and spasticity, sensory impairment, skeletal abnormalities, cardiac difficulties and diabetes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Friedreich Ataxia - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Friedreich Ataxia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Friedreich Ataxia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Friedreich Ataxia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 2, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Friedreich Ataxia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Friedreich Ataxia (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Friedreich Ataxia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Friedreich Ataxia (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Friedreich Ataxia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Friedreich Ataxia (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Friedreich Ataxia (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Friedreich Ataxia (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Friedreich Ataxia - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Friedreich Ataxia - Overview
Friedreich Ataxia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Friedreich Ataxia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Friedreich Ataxia - Companies Involved in Therapeutics Development
Adverum Biotechnologies Inc
Agios Pharmaceuticals Inc
BioElectron Technology Corp
BioMarin Pharmaceutical Inc
Biovista Inc
Horizon Pharma Plc
Ixchel Pharma LLC
Pfizer Inc
PTC Therapeutics Inc
Reata Pharmaceuticals Inc
STATegics Inc
Takeda Pharmaceutical Co Ltd
Voyager Therapeutics Inc
Friedreich Ataxia - Drug Profiles
(sodium phenylbutyrate + tauroursodeoxycholic acid) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADVM-063 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AGIL-FA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMN-290 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BVA-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BVA-203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Central Nervous System and Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTI-1601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dextro epicatechin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Frataxin for Friedreich's Ataxia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Frataxin for Friedreich's Ataxia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Frataxin for Friedrich's Ataxia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interferon gamma-1b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IXC-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JOT-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omaveloxolone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RT-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RT-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Friedreich Ataxia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Frataxin for Friedreich Ataxia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STSE-15 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-831 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vatiquinone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VYFXN-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Friedreich Ataxia - Dormant Projects
Friedreich Ataxia - Discontinued Products
Friedreich Ataxia - Product Development Milestones
Featured News & Press Releases
May 18, 2018: Voyager Therapeutics Announces Additional Data at the American Society of Gene and Cell Therapy 2018 Annual Meeting
Aug 22, 2017: Jupiter Orphan Therapeutics Receives Orphan Drug Designation for its Trans-Resveratrol Product JOTROL for Treatment of Friedreich's Ataxia
Aug 03, 2017: Chondrial Announces FDA Orphan Drug Designation for CTI-1601, a Novel Investigational Technology for the Treatment of Friedreich's Ataxia
Dec 08, 2016: Horizon Pharma Announces Top line Results from Phase 3 Study of ACTIMMUNE (interferon gamma-1b) in Friedreich's Ataxia
May 05, 2016: Horizon Pharma Completes Target Enrollment of 90 Patients for Phase 3 Trial of ACTIMMUNE(R) (interferon gamma-1b) for the Treatment of People With Friedreich Ataxia
Aug 05, 2015: Key Patent Granted for AAVLife's Gene-Therapy Program to Treat Cardiomyopathy in Friedreich's Ataxia
Jun 05, 2015: Horizon Pharma Initiates Phase 3 Trial of ACTIMMUNE for the Treatment of People With Friedreich's Ataxia
Apr 10, 2015: Horizon Pharma Receives FDA Fast Track Designation for ACTIMMUNE in the Treatment of Friedreich's Ataxia
Feb 13, 2015: Horizon Pharma Submits Investigational New Drug Application for ACTIMMUNE in the Treatment of Friedreich's Ataxia
Oct 09, 2014: Horizon Pharma Announces Presentation of ACTIMMUNE Phase 2 Data in Friedreich's Ataxia
Oct 03, 2014: Horizon Pharma Receives Orphan-Drug Designation for ACTIMMUNE (Interferon gamma-1b) in Friedreich's Ataxia
Mar 17, 2014: FDA Awards Fast Track Status to Edison Pharmaceuticals' EPI-743 for Friedreich's Ataxia
Feb 04, 2014: FDA Grants Edison Pharmaceuticals' EPI-743 Orphan Status for Friedreich's Ataxia
Nov 04, 2013: Edison Pharmaceuticals, FARA, and USF Announce Initiation of EPI-743 Phase 2 Friedreich's Ataxia Clinical Trial in Adults with Point Mutations
Jan 08, 2013: STATegics Announces a New Grant from Friedreich's Ataxia Research Alliance
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Friedreich Ataxia, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Friedreich Ataxia - Pipeline by Adverum Biotechnologies Inc, H2 2018
Friedreich Ataxia - Pipeline by Agios Pharmaceuticals Inc, H2 2018
Friedreich Ataxia - Pipeline by BioElectron Technology Corp, H2 2018
Friedreich Ataxia - Pipeline by BioMarin Pharmaceutical Inc, H2 2018
Friedreich Ataxia - Pipeline by Biovista Inc, H2 2018
Friedreich Ataxia - Pipeline by Horizon Pharma Plc, H2 2018
Friedreich Ataxia - Pipeline by Ixchel Pharma LLC, H2 2018
Friedreich Ataxia - Pipeline by Pfizer Inc, H2 2018
Friedreich Ataxia - Pipeline by PTC Therapeutics Inc, H2 2018
Friedreich Ataxia - Pipeline by Reata Pharmaceuticals Inc, H2 2018
Friedreich Ataxia - Pipeline by STATegics Inc, H2 2018
Friedreich Ataxia - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Friedreich Ataxia - Pipeline by Voyager Therapeutics Inc, H2 2018
Friedreich Ataxia - Dormant Projects, H2 2018
Friedreich Ataxia - Discontinued Products, H2 2018

List of Figures
Number of Products under Development for Friedreich Ataxia, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Parkinson's Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects
    Published: 31-May-2019        Price: US 6995 Onwards        Pages: 84
    Parkinson's Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects Summary Parkinson's disease (PD), a progressive neurological disorder that affects movement control, is associated with considerable quality of life impairments and burden of care, particularly in the advanced disease stages. Cognitive and behavioral complications of PD are common. PD-associated deme......
  • Global Central Nervous System Disorders Therapeutics Market Size, Status and Forecast 2019-2025
    Published: 22-May-2019        Price: US 3900 Onwards        Pages: 99
    Central Nervous System (CNS) disorders are also called as neurological and psychiatric disorders. CNS disorders can affect either the brain or spinal cord, or both. Depression is the dominated market of CNS Disorders Therapeutics In 2018, the global Central Nervous System Disorders Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of 3.4% during 2019-2025. This report focuses on the global Central ......
  • Global CNS Therapeutics Market Size, Status and Forecast 2019-2025
    Published: 13-May-2019        Price: US 3900 Onwards        Pages: 109
    Central nervous system (CNS) disease is a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function. The condition may be an inherited metabolic disorder; the result of damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or multiple factors. Movement disorders such as Parkinson's disease, dystonia, and essential tremor are central nervous system conditions. What they ha......
  • Global CNS Therapeutics Industry Market Research Report
    Published: 02-May-2019        Price: US 2960 Onwards        Pages: 109
    The CNS Therapeutics market revenue was xx.xx Million USD in 2014, grew to xx.xx Million USD in 2018, and will reach xx.xx Million USD in 2024, with a CAGR of x.x% during 2019-2024. Based on the CNS Therapeutics industrial chain, this report mainly elaborates the definition, types, applications and major players of CNS Therapeutics market in details. Deep analysis about market status (2014-2019), enterprise competition pattern, advantages and disadvantages of enterprise products, industry develo......
  • CNS Therapeutics Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 20-Apr-2019        Price: US 3000 Onwards        Pages: 146
    CNS Therapeutics Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global CNS Therapeutics industry with a focus on the Chinese market. The report provides key statistics on the market status of the CNS Therapeutics manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2014-2024 global and Chinese CNS Therapeutic......
  • Global CNS Therapeutics Industry Market Research 2019
    Published: 15-Feb-2019        Price: US 2600 Onwards        Pages: 162
    In this report, we analyze the CNS Therapeutics industry from two aspects. One part is about its production and the other part is about its consumption. In terms of its production, we analyze the production, revenue, gross margin of its main manufacturers and the unit price that they offer in different regions from 2014 to 2019. In terms of its consumption, we analyze the consumption volume, consumption value, sale price, import and export in different regions from 2014 to 2019. We also make a p......
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Insight, 2019
    Published: 15-Jan-2019        Price: US 1250 Onwards        Pages: 50
    "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Insight, 2019" report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indica......
  • Bacterial (Pyogenic) Meningitis - Pipeline Insight, 2019
    Published: 15-Jan-2019        Price: US 1250 Onwards        Pages: 50
    "Bacterial (Pyogenic) Meningitis - Pipeline Insight, 2019" report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Bacterial (Pyogenic) Meningitis development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.......
  • Bacterial (Pyogenic) Meningitis - Epidemiology Forecast to 2028
    Published: 15-Jan-2019        Price: US 3250 Onwards        Pages: 50
    DelveInsight's "Bacterial (Pyogenic) Meningitis - Epidemiology Forecast, 2028" report provides a comprehensive analysis of the Bacterial (Pyogenic) Meningitis epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028. Markets Covered - United States - EU5 (Germany, France, Italy, Spain, and the United Kingdom) - Japan Study Period: 2016-2028 Bacterial (Pyogenic) Meningitis Epi......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs